YM-155

Confirm delete?

YM-155

Zoom

Cat No: 11490

Biochemicals - Small Molecule Inhibitors

Survivin, a member of the inhibitor of apoptosis (IAP) family, plays an important role in drug resistance and cancer cell survival in many types of cancer. YM-155 is a novel small molecule that suppresses transactivation of survivin through direct bind...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4,9-dihydro-1-(2-methoxyethyl)2-methyl-4,9-dioxo-3-(2-pyrazinylmethyl)-1H-naphth[2,3-d]imidazolium, bromide

Correlated keywords:

transcriptions factors cancers apoptosis sepantronium survivin IAP inhibitors inhibits inhibitions drugs 753440-91-4 resistances anti-tumors antitumors anti tumors YM155 YMs 155 transactivation promoters suppresses suppression p53 prostate pancreatic lung

Product Overview:
Survivin, a member of the inhibitor of apoptosis (IAP) family, plays an important role in drug resistance and cancer cell survival in many types of cancer. YM-155 is a novel small molecule that suppresses transactivation of survivin through direct binding to its promoter.{22213} It selectively suppresses expression of survivin and induces apoptosis in p53-deficient cancer cells in vitro at 10 nM.{22212} At concentrations up to 100 nM, YM-155 has little effect on expression levels of other IAP- or Bcl-2-related proteins.{22212} YM-155 exerts anti-tumor effects in various in vivo cancer models, including prostate, pancreatic, and lung cancer.{22212,22211}

Size	1 mg
Shipping	dry ice
CAS Number	781661-94-7
Molecular Formula	C₂₀H₁₉N₄O₃ • Br
SMILES	O=C(C1=C2N(CCOC)C(C)=[N+]1CC3=CN=CC=N3)C4=CC=CC=C4C2=O.[Br-]
Molecular Weight	443,3
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.